Search | Clinical Trials Finder

Conditions: Acute Kidney Injury Due to Sepsis
Interventions: TIN816 70 mg lyophilisate powder, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more

Conditions: Asthma
Interventions: Mepolizumab, Placebo, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more

Conditions: Sinusitis Chronic
Interventions: GLS-1200, Placebo; Drug
Lead sponsor: GeneOne Life Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Venous Thrombosis
Interventions: JETi lower extremity venous thrombosis; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 21
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more

Conditions: Obesity, Overweight or Obesity
Interventions: MET097, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Hollywood, Florida • Tampa, Florida • Decatur, Georgia + 2 more

Conditions: Diabetic Foot Ulcer
Interventions: Dual-layer perinatal tissue allograft, Three-layer fenestrated perinatal tissue allograft, Standard of care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Monroe, North Carolina

Conditions: Brain Metastases, Solid Tumors
Interventions: 2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10), Stereotactic Radio-Surgery (SRS) therapy, Positron Emission Tomography; Drug · Radiation · Procedure
Lead sponsor: Aposense Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania

Conditions: Sepsis Syndrome
Interventions: MMR vaccine; Biological
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Geographic Atrophy, Age Related Macular Degeneration
Interventions: IONIS-FB-Lrx, Placebo (sterline saline 0.9%); Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Encino, California + 20 more

Conditions: Abscess
Interventions: Methylene Blue, 20% I.V. Fat Emulsion, Insertion of optical fiber, Laser illumination, 5 minutes, Laser illumination, 10 minutes, Laser illumination, 15 minutes, Laser illumination, 20 minutes, Laser illumination, 25 minutes, Laser illumination, 30 minutes, Optical spectroscopy measurement; Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Obsessive-Compulsive Disorder
Interventions: RR-HNK/Hydroxynorketamine, Placebo; Drug
Lead sponsor: Carolyn Rodriguez; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Smoking Cessation, Weight Gain
Interventions: Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: COVID-19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 47
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more

Conditions: Gingival Recession, Lack of Keratinized Attached Peri-implant Mucosa, Thin Gingiva
Interventions: Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM), Free Gingival graft; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Volunteers
Interventions: Unfractionated heparin (UFH), Bendavia, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Neridronic acid 100 mg, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more

Conditions: Pelvic Floor Disorders
Interventions: Bladder scan post void residual, Straight catheter post void residual, Back fill voiding trial; Device · Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Subjects
Interventions: AC-076 for s.c. administration, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 981 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Loxahatchee Groves, Florida • Miami, Florida • Rock Hill, South Carolina + 1 more

Conditions: Shigella Infection
Interventions: Placebo, WRSs2, WRSs3; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lipoma
Interventions: Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Mixed Dyslipidemia
Interventions: ARO-APOC3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more

Conditions: Non-segmental Vitiligo
Interventions: EI-001, Placebo; Biological · Other
Lead sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Huntington Beach, California • Hollywood, Florida • Worcester, Massachusetts + 2 more

Search by objective public record fields.

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

JETi Lower Extremity Venous Thrombosis

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities

Pilot Study of RR-HNK in OCD

Exenatide for Smoking Cessation and Prevention of Weight Gain

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

Accuracy of Bladder Scanners in Post-operative Voiding Trials

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients